Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.68 USD
-0.02 (-2.24%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.68 0.00 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CARA 0.68 -0.02(-2.24%)
Will CARA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARA
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
CARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
Other News for CARA
Marijuana Stock Movers For April 25, 2024
Marijuana Stock Movers For April 23, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Bearish Sentiment Across The Cannabis Space - Check Full Movers For April 18, 2024
Bearish Monday For Marijuana Stocks - AusCann Group Holdings, Target Group Among Top Gainers